Market Herald logo


Be the first with the news that moves the market
  • Impression Healthcare has appointed John Michailidis as CEO of its medicinal hemp drug division
  • John is an experienced executive with a long and successful career in developing medical drugs and bringing them to market
  • Before this role, John worked in multiple companies such as Roche in Korea and Teva Pharmaceuticals
  • Impression’s share price is up 5.63 per cent today with shares currently trading for 7.5 cents apiece

Impression Healthcare has appointed John Michailidis as CEO of its medicinal hemp drug discovery division, Incannex.

John will be joining Dr Sud Agarwal and the Medical Advisory Board to create a market leading cannabinoid pharmaceutical discovery team.

“I’m thrilled to be working alongside John to commercialise our novel clinical assets,” Dr Sud said,

“John brings enthusiasm, vigour and maturity into our drug discovery processes. He has demonstrated solid commercial acumen over his long and successful tenure in the pharmaceutical sector,” he added.

John is an experienced pharmaceutical executive with an extensive and successful career in developing novel drugs and successfully bringing them to market.

He holds a Bachelor of Science (Honours), an executive MBA from Harvard Business School and is a member of The Australian Institute of Company Directors.

Before joining Incannex, John was the founding Managing Director of Teva Pharmaceuticals where he quickly established a significant commercial operation.

In this role, he successfully closed several licensing and partnering deals worth over $10 million per year and increased sales to $100 million by 2017.

John has also spent seven years with world-leading pharmaceutical company Roche Holding AG, where he was the Global Business Director – Strategic Marketing, and before that was President and CEO of Roche Korea.

During his time at Roche Korea, he launched key new treatments into the Korean market, tripled sales in a two-year period and gained patient reimbursement status for various medical treatments.

The company hopes that by appointing John as the CEO of Incannex, it will form part of the continued and significant strengthening of Impression’s drug development team.

“I’m delighted to join a company that is committed to a proper, scientifically principled and sound commercialisation strategy,” John said.

“Dr Sud Agarwal and I are excited to fully develop a world-class medicinal cannabis company to commercialise our novel cannabinoid drugs,” he added.

Impression Healthcare’s share price is up 5.63 per cent today with shares trading for 7.5 cents apiece at 2:35 pm AEDT.

IHL by the numbers
More From The Market Herald
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).